ESR1 and glioblastoma: The evidence that Losartan (LOS) inhibits the stimulatory effect of Ang II in glioblastoma cell proliferation to a significantly greater extent than ICI as revealed by the Ki-67 immunostaining score indicates that such inhibitory effect does not come exclusively from the concomitant downregulation of estrogen receptor-α signaling, but depends on additional events mostly related to the previous described antiangiogenetic and antifibrotic effect of LOS [37,38,39,40,41].